Want to see GALT full AI Analyst Report?
Top Page
Galectin Therapeutics
(NASDAQ:GALT)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.50
▼(-15.66% Downside)
Action:Reiterated
Date:09/06/26
Overall score is held back primarily by very weak financial performance (no revenue, ongoing losses/cash burn, and historically stressed balance sheet). Offsetting factors include strong recent technical momentum and constructive corporate developments, particularly the large debt reduction and FDA alignment for Phase 3, while valuation support is limited due to negative earnings and no stated dividend yield.
Positive Factors
Major debt reduction
The debt-to-equity conversion materially reduces obligations and interest-related pressure, strengthening financial flexibility for a company with ongoing development costs. Continued support from the largest shareholder and an undrawn facility may provide additional capacity to advance clinical programs.
Negative Factors
No revenue and persistent losses
The absence of revenue means the company has not yet established a commercial funding engine, while recurring operating and net losses continue to consume capital. Until a candidate reaches commercialization, financial performance remains dependent on funding and successful clinical execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Major debt reduction
The debt-to-equity conversion materially reduces obligations and interest-related pressure, strengthening financial flexibility for a company with ongoing development costs. Continued support from the largest shareholder and an undrawn facility may provide additional capacity to advance clinical programs.
Read all positive factors
Galectin Therapeutics (GALT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$339.86M
Dividend YieldN/A
Average Volume (3M)258.99K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue GrowthN/A
EPS Growth33.25%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding100,849,650
10 Day Avg. Volume196,259
30 Day Avg. Volume258,992
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap1.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-31.44
Forecast
1Y Price Target
$11.00Price Target Upside165.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Galectin Therapeutics Business Overview & Revenue Model
Company Description
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship...
Galectin Therapeutics Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
3
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.75M | -23.45M | -41.47M | -38.24M | -37.71M | -30.00M |
| Net Income | -27.84M | -30.84M | -47.05M | -41.07M | -38.78M | -30.53M |
Balance Sheet | ||||||
| Total Assets | 14.83M | 19.53M | 17.50M | 28.20M | 21.29M | 41.83M |
| Cash, Cash Equivalents and Short-Term Investments | 13.27M | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M |
| Total Debt | 137.70M | 133.76M | 106.25M | 71.81M | 39.87M | 29.06M |
| Total Liabilities | 151.68M | 145.73M | 120.56M | 88.44M | 53.48M | 39.21M |
| Stockholders Equity | -136.85M | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M |
Cash Flow | ||||||
| Free Cash Flow | -15.89M | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Operating Cash Flow | -15.89M | -23.88M | -41.77M | -32.97M | -31.06M | -24.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 15.39M | 26.48M | 31.23M | 40.03M | 10.00M | 36.81M |
Galectin Therapeutics Technical Analysis
Negative
4.15
Price Trends
3.83
Negative
3.67
Negative
3.20
Positive
Market Momentum
-0.10
Positive
36.77
Neutral
10.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GALT, the sentiment is Negative. The current price of 4.15 is above the 20-day moving average (MA) of 3.74, above the 50-day MA of 3.83, and above the 200-day MA of 3.20, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 36.77 is Neutral, neither overbought nor oversold. The STOCH value of 10.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GALT.
Galectin Therapeutics Risk Analysis
Galectin Therapeutics disclosed 37 risk factors in its most recent earnings report. Galectin Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galectin Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.20B | 8.51 | -109.40% | ― | ― | ― | |
54 Neutral | $339.86M | -7.89 | 21.48% | ― | ― | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $426.66M | -4.78 | -35.26% | ― | ― | -13.09% | |
45 Neutral | $962.23M | -5.50 | -49.11% | 23.67% | ― | 91.41% | |
42 Neutral | $134.94M | -1.12 | -57.92% | ― | -19.07% | 2.07% | |
40 Underperform | $91.93M | -0.74 | -108.05% | ― | ― | 45.08% |
* Healthcare Sector Average
GALT
Galectin Therapeutics
3.38
-1.75
-34.11%
OMER
Omeros
16.86
9.21
120.39%
VYGR
Voyager Therapeutics
1.86
-2.69
-59.12%
TECX
Tectonic Therapeutic
21.09
3.70
21.28%
JBIO
Jade Biosciences
14.91
4.98
50.15%
TNYA
Tenaya Therapeutics
0.39
-1.29
-76.90%
Galectin Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion
Positive
Aug 4, 2026
On July 31, 2026, Galectin Therapeutics converted all outstanding principal and accrued interest under five line-of-credit facilities held by chairman and major shareholder Richard E. Uihlein into equity, issuing 34,376,167 common shares. The move...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.